Nuevecor lands $24m Series A
Nuevocor, a preclinical-stage biotech company specializing in gene therapy for cardiomyopathies, has secured $24 million in Series A financing.
Nuevocor, a preclinical-stage biotech company specializing in gene therapy for cardiomyopathies, has secured $24 million in Series A financing.